Potential implications of the new pharmacotherapies on obesity management The mean WL in clinical trials with the most efficacious new obesity pharmacotherapies ranges between 15% and 25% at 1 year (and it may be even higher for some agents that have not reached weight plateau at study completion)
Medications requiring particular consideration with Rybelsus include: Levothyroxine (thyroid hormone replacement) - monitor thyroid function as semaglutide may increase levothyroxine exposure Warfarin and other anticoagulants - monitor INR when initiating semaglutide Insulin and sulfonylureas (increased risk of hypoglycaemia, dose adjustment may be needed) According to the Rybelsus Summary of Product Characteristics (SmPC), patients should take the medication correctly: on an empty stomach with no more than 120ml of water, swallow the tablet whole, and wait at least 30 minutes before any food, drink, or other oral medications
IL-21 stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma
UC Davis Health examines systemic impact of GLP-1based therapies (SACRAMENTO) GLP-1 agonists are reshaping modern health care, delivering benefits that reach far beyond glycemic control and weight loss
Molecular-genetic analysis of AZF gene defects located on Y-chromosome, and CFTR gene in male infertility
